Select Page

A global pharmaceutical giant engaged Shift Health to explore additional RNA virus indications to inform lifecycle management for a promising antiviral in clinical development for COVID-19.

Recognizing the significant socioeconomic burden and potential global risk across the spectrum of RNA viruses—including Influenza, RSV, Ebola, Zika,  Dengue, MERS-CoV and SARS-CoV-1—we developed a set of weighted criteria to prioritize targets for future clinical development. We uncovered critical nuances to better understand the global epidemiology and burden, unmet medical needs, market dynamics, and feasibility and access considerations for each indication. Based on our analysis, we prioritized specific indications and identified strategic considerations for unlocking value in different settings, including inpatient and outpatient care, the travel market and government stockpiling for pandemic preparedness.

Our analysis provided the client with critical insights to guide lifecycle planning and ensure that the antiviral asset delivers patient and societal value beyond the COVID-19 pandemic.